How FLT3 signaling affects leukemia development
Official title: Regulation of FLT3 Signaling in Leukemia
Funded at Children's Hosp of Philadelphia · NIH-10916444 · Data updated 2026-11-12
This study is looking at how changes in a specific protein called FLT3 affect the behavior of acute myeloid leukemia (AML) and aims to find new ways to help patients by fixing these changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Hosp of Philadelphia NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $604,938 |
| NIH project number | 5R01CA282668-02 |
| Project ID | NIH-10916444 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with FLT3 mutations.
✕Less likely to help
Patients with other types of leukemia or those without FLT3 mutations may not benefit from this research.
What this research studies
This research investigates the role of FLT3 signaling in acute myeloid leukemia (AML) by examining how post-translational modifications, particularly palmitoylation, influence the behavior of FLT3 proteins. The study aims to understand how mutations in FLT3 lead to abnormal signaling pathways that contribute to leukemia progression. By disrupting the palmitoylation of oncogenic FLT3 mutants, researchers hope to redirect these proteins to their proper locations within the cell, potentially altering their signaling and impact on leukemia. This approach could provide insights into new therapeutic strategies for AML patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve outcomes for patients with acute myeloid leukemia.
How similar studies have gone: Other research has shown promising results in targeting signaling pathways in leukemia, suggesting that this approach may also yield significant findings.
Where this research is happening
-
Children's Hosp of Philadelphia
Philadelphia, United States Active
Researchers
- Principal investigator: Tong, Wei — Children's Hosp of Philadelphia
- Study coordinator: Tong, Wei
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.